Existing therapies rely on drops or injections to deliver medicine, and often do not reach the retina or the inside of cells. iVeena uses novel approaches — including drug delivery from the lens capsule, minimally invasive implants, and intracellular therapy — to reach target tissues for better patient outcomes.


iVeena has nine products in late pre-clinical and research phase. Targeted indications include Post Surgery Cataract Inflammation, Macular Degeneration (Wet AMD), Diabetic Retinopathy, Glaucoma, and three orphan drug candidates.

iVeena Pipeline 0612172x

Back to top